Trifluridine

Trifluridine
Clinical data
Trade names	Viroptic; Lonsurf (+tipiracil)
Other names	α,α,α-trifluorothymidine; 5-trifluromethyl-2′-deoxyuridine; FTD5-trifluoro-2′-deoxythymidine; TFT; CF3dUrd; FTD; F3TDR; F3Thd
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
Routes of; administration	Eye drops; tablets (+tipiracil)
ATC code	S01AD02 (WHO) L01BC59 (WHO);
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Bioavailability	Negligible (eye drops);; ≥57% (oral)
Protein binding	>96%
Metabolism	Thymidine phosphorylase
Elimination half-life	12 minutes (eye drops);; 1.4–2.1 hrs (combination with tipiracil)
Excretion	Mostly via urine
Identifiers
	IUPAC name 1-[4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)-(1H,3H)-pyrimidine-2,4-dione;
CAS Number	70-00-8 ;
PubChem CID	6256;
DrugBank	DB00432 ;
ChemSpider	6020 ;
UNII	RMW9V5RW38;
KEGG	D00391 ;
ChEBI	CHEBI:75179 ;
ChEMBL	ChEMBL1129 ;
CompTox Dashboard (EPA)	DTXSID4046602 ;
ECHA InfoCard	100.000.657
Chemical and physical data
Formula	C10H11F3N2O5
Molar mass	296.202 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)C=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO;
	InChI InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1 ; Key:VSQQQLOSPVPRAZ-RRKCRQDMSA-N ;
	(what is this?) (verify)

Trifluridine (also called trifluorothymidine; abbreviation TFT or FTD^[1]) is an anti-herpesvirus antiviral drug, used primarily as prescription eyedrops. It was sold under the trade name Viroptic by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now wholly owned by King Pharmaceuticals.

Trifluridine was approved for medical use in 1980.^[2] It is also a component of the anti-cancer drug trifluridine/tipiracil, which is taken by mouth.

^ Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, et al. (December 2021). "Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center". The Oncologist. 26 (12): e2161–e2169. doi:10.1002/onco.13942. PMC 8649060. PMID 34406678.
^ Kimberlin DW (2012). "Antiviral Agents". In Long SS, Pickering LK, Prober CG (eds.). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN 978-1437727029.

[1] Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, et al. (December 2021). "Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center". The Oncologist. 26 (12): e2161–e2169. doi:10.1002/onco.13942. PMC 8649060. PMID 34406678.

[2] Kimberlin DW (2012). "Antiviral Agents". In Long SS, Pickering LK, Prober CG (eds.). Principles and Practice of Pediatric Infectious Disease. Elsevier Health Sciences. p. 1502. ISBN 978-1437727029.

[1]

[2]